62621-09-4

Basic information

• Product Name: Methyl 2-Methyl-4-nitrobenzoate
• Synonyms: Methyl 2-Methyl-4-nitrobenzoate;Benzoic acid, 2-Methyl-4-nitro-, Methyl ester;Methyl 4-Nitro-2-Methylbenzoate;2-Methyl-4-nitrobenzoic acid methyl ester;_x005f\rMethyl 2-Methyl-4-nitrobenzoate
• CAS NO: 62621-09-4
• Molecular Formula: C₉H₉NO₄
• Molecular Weight: 195.18
• Product Categories: Esters;Phenyls & Phenyl-Het
• Mol File: 62621-09-4.mol

Chemical Properties

• Melting Point: 74.0 to 78.0 °C
• Boiling Point: 315.445 °C at 760 mmHg
• Flash Point: 148.51 °C
• Appearance: /
• Density: 1.256 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.548
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• CAS DataBase Reference: Methyl 2-Methyl-4-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-Methyl-4-nitrobenzoate(62621-09-4)
• EPA Substance Registry System: Methyl 2-Methyl-4-nitrobenzoate(62621-09-4)

Safety Data

• Hazardous Substances Data: 62621-09-4(Hazardous Substances Data)

Usage

Uses

methyl 2-methyl-4-nitrobenzoate is a useful research chemical.

InChI:InChI=1/C9H9NO4/c1-6-5-7(10(12)13)3-4-8(6)9(11)14-2/h3-5H,1-2H3

Upstream product

• 67-56-1 methanol 
• 30459-70-2 2-methyl-4-nitrobenzoyl chloride 
• 201230-82-2 carbon monoxide 
• 5326-38-5 2-iodo-5-nitrotoluene 
• 1975-51-5 2-methyl-4-nitrobenzoic acid 
• 74-88-4 methyl iodide 
• 124-41-4 sodium methylate 
• 99-52-5 2-methyl-4-nitro-benzenamine 
• 89001-53-6 2-cyano-5-nitrotoluene 
• 99584-16-4 2-methyl-4-nitro-benzoic acid amide 

Downstream Products

• 133446-99-8 2-bromomethyl-4-nitro-benzoic acid methyl ester 
• 928032-23-9 6-nitroisoquinolin-1(2H)-one 
• 246545-31-3 2-{5-[(2-acetylamino-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-6-ylmethyl)-formyl-amino]-1-oxo-1,3-dihydro-isoindol-2-yl}-5-benzyloxycarbonylamino-pentanoic acid methyl ester 
• 246545-30-2 methyl 2-L-(5-amino-2,3-dihydro-1-oxo-2(1H)-isoindolyl)-5-[N-(benzyloxycarbonyl)amino]pentanoate 
• 246545-29-9 methyl 2-L-(2,3-dihydro-5-nitro-1-oxo-2(1H)-isoindolyl)-5-[N-(benzyloxycarbonyl)amino]pentanoate 
• 807343-00-6 2-benzyl-5-nitroisoindolin-1-one 
• 914646-64-3 (E)-3-(2-benzyl-1-oxoisoindolin-5-yl)-N-(tetrahydro-2H-pyran-2-yloxy)acrylamide 
• 914646-61-0 methyl 3-(2-benzyl-1-oxoisoindolin-5-yl)-2-bromopropanoate 
• 914646-63-2 (E)-3-(2-benzyl-1-oxoisoindolin-5-yl)acrylic acid 
• 914646-62-1 (E)-methyl 3-(2-benzyl-1-oxoisoindolin-5-yl)acrylate 
• 914646-60-9 5-amino-2-benzylisoindolin-1-one 
• 924266-51-3 8-(2-fluoro-4-nitrophenylamino)-6H-dibenzo[b,e]oxepin-11-one 
• 924266-47-7 8-(4-nitrophenylamino)-6H-dibenzo[b,e]oxepin-11-one 
• 915034-92-3 8-(2-nitrophenylamino)-6H-dibenzo[b,e]oxepin-11-one 

Relevant articles and documents

Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands

Proteolysis targeting chimeras (PROTACs) hijacking the cereblon (CRBN) E3 ubiquitin ligase have emerged as a novel paradigm in drug development. Herein we found that linker attachment points of CRBN ligands highly affect their aqueous stability and neosubstrate degradation features. This work provides a blueprint for the assembly of future heterodimeric CRBN-based degraders with tailored properties.

A kind of diaryl hydanto?n derivatives, its preparation method, pharmaceutical composition and application

Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treating androgen receptor related diseases.

MONOCARBOXYLATE TRANSPORT MODULATORS AND USES THEREOF

The invention generally relates to the field of monocarboxylate transport modulators, e.g., monocarboxylate transport inhibitors, and more particularly to new substituted-quinolone compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in treating, modulating, forestalling and/or reducing physiological conditions associated with monocarboxylate transport activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, obesity, diabetes, cardiovascular diseases, tissue and organ transplant rejection, and malaria.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of one or more protein kinases. Such compounds have general formula I or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, W, Ry, R3 and R4 are as defined herein.

Method for synthesizing 2-azidomethyl-4-nitrobenzoyl chloride

The invention provides a synthetic route for a novel protective group, namely 2-azidomethyl-4-nitrobenzoyl chloride. 2-methyl-4-nitrobenzoic acid is used as a raw material, and the 2-azidomethyl-4-nitrobenzoyl chloride is synthesized through the five step

BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS

Disclosed are promoieties of the following formula which can be used to form prodrugs of nitrogen-containing or hydroxyl-containing drug or a pharmaceutically active agent: (I) and pharmaceutical compositions comprising the prodrugs.

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

MACROCYCLIC FACTOR VIIA INHIBITORS

The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.

MACROCYCLIC FACTOR VIIA INHIBITORS

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.

DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS

The present invention relates to compounds of the formula I wherein R1, R2, R3, R4, X and Y have the meanings given in the description. The compounds have an action which is immunomodulating and inhibits or regulates the release of IL-1β and/or TNF-α. The